Adjuvant treatment of premenopausal women with endocrine-responsive early breast cancer: design of the TEXT and SOFT trials

Regan, Meredith M; Pagani, Olivia; Fleming, Gini F; Walley, Barbara A; Price, Karen N; Rabaglio, Manuela; Maibach, Rudolf; Ruepp, Barbara; Coates, Alan S; Goldhirsch, Aron; Colleoni, Marco; Gelber, Richard D; Francis, Prudence A (2013). Adjuvant treatment of premenopausal women with endocrine-responsive early breast cancer: design of the TEXT and SOFT trials. Breast, 22(6), pp. 1094-1100. Elsevier 10.1016/j.breast.2013.08.009

Full text not available from this repository. (Request a copy)

OBJECTIVES

In 2003 the International Breast Cancer Study Group (IBCSG) initiated the TEXT and SOFT randomized phase III trials to answer two questions concerning adjuvant treatment for premenopausal women with endocrine-responsive early breast cancer: 1-What is the role of aromatase inhibitors (AI) for women treated with ovarian function suppression (OFS)? 2-What is the role of OFS for women who remain premenopausal and are treated with tamoxifen?

METHODS

TEXT randomized patients to receive exemestane or tamoxifen with OFS. SOFT randomized patients to receive exemestane with OFS, tamoxifen with OFS, or tamoxifen alone. Treatment was for 5 years from randomization.

RESULTS

TEXT and SOFT successfully met their enrollment goals in 2011. The 5738 enrolled women had lower-risk disease and lower observed disease-free survival (DFS) event rates than anticipated. Consequently, 7 and 13 additional years of follow-up for TEXT and SOFT, respectively, were required to reach the targeted DFS events (median follow-up about 10.5 and 15 years). To provide timely answers, protocol amendments in 2011 specified analyses based on chronological time and median follow-up. To assess the AI question, exemestane + OFS versus tamoxifen + OFS, a combined analysis of TEXT and SOFT became the primary analysis (n = 4717). The OFS question became the primary analysis from SOFT, assessing the unique comparison of tamoxifen + OFS versus tamoxifen alone (n = 2045). The first reports are anticipated in mid- and late-2014.

CONCLUSIONS

We present the original designs of TEXT and SOFT and adaptations to ensure timely answers to two questions concerning optimal adjuvant endocrine treatment for premenopausal women with endocrine-responsive breast cancer. Trial Registration TEXT: Clinicaltrials.govNCT00066703 SOFT: Clinicaltrials.govNCT00066690.

Item Type:	Journal Article (Original Article)
Division/Institute:	04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Medical Oncology
UniBE Contributor:	Rabaglio, Manuela Elena
Subjects:	600 Technology > 610 Medicine & health
ISSN:	0960-9776
Publisher:	Elsevier
Language:	English
Submitter:	Marianne Zahn
Date Deposited:	01 Apr 2014 13:39
Last Modified:	02 Mar 2023 23:24
Publisher DOI:	10.1016/j.breast.2013.08.009
PubMed ID:	24095609
Uncontrolled Keywords:	Adjuvant therapy, Early breast cancer, Endocrine-responsive, Premenopausal, Trial design
URI:	https://boris.unibe.ch/id/eprint/45055